Italia markets open in 4 hours 57 minutes

Dynavax Technologies Corporation (0IDA.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
11,42+0,31 (+2,79%)
Alla chiusura: 06:46PM BST

Dynavax Technologies Corporation

2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com

Settore/i
Settore
Impiegati a tempo pieno408

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Ryan SpencerCEO, Interim CFO & Director1,49MN/D1978
Mr. David F. NovackPresident & COO1,01M1,51M1962
Dr. Robert Janssen M.D.Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs861,52k251,32k1954
Ms. Kelly MacDonaldSenior VP & CFO (Leave of Absence)788,55kN/D1984
Mr. Justin BurgessChief Accounting Officer & ControllerN/DN/DN/D
Mr. Jeff P. CoonSenior VP & Chief Human Resources OfficerN/DN/D1963
Mr. Paul CoxVP of Investor Relations & Corporate CommunicationsN/DN/DN/D
Mr. John L. SlebirSenior VP & General CounselN/DN/D1966
Mr. Donn CasaleSenior VP & Chief Commercial OfficerN/DN/DN/D
Dr. Dong YuSenior Vice President of Vaccine ResearchN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Governance aziendale

L'ISS Governance QualityScore di Dynavax Technologies Corporation al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 7; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.